-
公开(公告)号：EP1991571A2
公开(公告)日：2008-11-19
申请号：EP07751276.2
申请日：2007-02-16
申请人： The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services , The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
IPC分类号： C07K14/435 , C12N15/86
CPC分类号： C07K14/005 , A61K38/00 , A61K39/12 , A61K39/145 , A61K2039/53 , C07K2319/21 , C07K2319/70 , C12N2710/10343 , C12N2740/16043 , C12N2740/16134 , C12N2760/16122 , C12N2760/16134
摘要： These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and/or contain modifications to protease cleavage sites of HA which affect the normal function of the protein. Adenoviral constructs expressing the same inserts have been engineered for prime boost strategies. Protein-based vaccines based on protein production from insect or mammalian cells using foldon trimerization stabilization domains with or without cleavage sites to assist in purification of such proteins have been developed. Another embodiment of this invention is the work with HA pseudotyped lentiviral vectors which would be used to screen for neutralizing antibodies in patients and to screen for diagnostic and therapeutic antivirals such as monoclonal antibodies.
-
公开(公告)号：EP4382127A3
公开(公告)日：2024-08-28
申请号：EP24165266.8
申请日：2016-11-08
申请人： The Children's Hospital of Philadelphia , The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
IPC分类号： A61K39/395 , A61P35/00 , C07K16/18 , C12P21/08 , A61K47/68 , A61K47/69 , A61K39/00 , C07K16/30 , A61K35/17 , A61K45/06
摘要： The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen.
-
公开(公告)号：EP4183411A1
公开(公告)日：2023-05-24
申请号：EP22204593.2
申请日：2014-03-12
申请人： Takeda Vaccines, Inc. , The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services
IPC分类号： A61K39/12
摘要： Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
-
公开(公告)号：EP3175859B1
公开(公告)日：2020-09-23
申请号：EP16196935.7
申请日：2008-05-30
IPC分类号： A61K31/7008 , A61P13/12 , A61P21/00
-
公开(公告)号：EP3248642B1
公开(公告)日：2020-04-08
申请号：EP17173542.6
申请日：2013-06-24
申请人： The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services , Creare, Incorporated
-
公开(公告)号：EP2258428B1
公开(公告)日：2019-11-27
申请号：EP10008772.5
申请日：2005-04-01
申请人： The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services , Creare Inc.
-
公开(公告)号：EP3466440A1
公开(公告)日：2019-04-10
申请号：EP18201391.2
申请日：2011-04-15
申请人： The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services , GlaxoSmithKline Biologicals SA
发明人： Sullivan, Nancy J. , Nabel, Gary J. , Asiedu, Clement , Cheng, Cheng , Nicosia, Alfredo , Cortese, Riccardo , Ammendola, Virginia , Colloca, Stefano
摘要： This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
-
公开(公告)号：EP2758076B1
公开(公告)日：2018-12-12
申请号：EP12761739.7
申请日：2012-09-21
申请人： CSL Behring GmbH , The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services
发明人： BASTA, Milan , CHEN, Xinzhi , MATTSON, Mark
IPC分类号： A61K39/395 , A61K38/55 , A61P9/10
CPC分类号： A61K39/39516 , A61K38/55 , A61K38/57 , A61K45/06 , A61K2039/505 , C07K16/06 , A61K2300/00
摘要： Methods are disclosed for treating cerebral ischemia using a combination of C1-INH and immunoglobulin, such as human plasma derived immunoglobulin (IVIG).
-
公开(公告)号：EP2668299B1
公开(公告)日：2018-03-07
申请号：EP12740015.8
申请日：2012-01-26
发明人： THOMAS, Jennifer, Dolan , WANG, Xin , HATCHER, Cynthia , ANDERSON, Raydel , THEODORE, Mary, Jordan , MAYER, Leonard, W.
CPC分类号： C12Q1/689 , C12Q1/701 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16
摘要： A process for detecting Haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a Haemophilus influenzae nucleotide sequence and measuring the amplification product to detect Haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay. Also provided are reagents and methods for detecting and distinguishing Haemophilus influenzae from other infectious agents. A kit is provided for detecting and quantifying Haemophilus influenzae in a sample.
-
公开(公告)号：EP3248642A1
公开(公告)日：2017-11-29
申请号：EP17173542.6
申请日：2013-06-24
申请人： The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services , Creare, Incorporated
发明人： PAPANIA, Mark, J. , BARRY, James, J , BAGLEY, Mark, C. , KNAUS, Darin, A. , FRIETS, Eric, M. , MOYNIHAN, Edward
摘要： A nasal delivery device can include air-receiving section that has a first passageway therethrough to allow air to pass through the air-receiving section, a powder-reservoir receiving section sized to receive a powder reservoir, and a powder-delivery section that has a second passageway therethrough to allow aerosolized powder from the powder reservoir to pass through the powder-delivery section. The first passageway can have a first end and a second end, with the first end being further from the powder-reservoir receiving section and the second end being at or near the powder-reservoir receiving area. The second end of the air-receiving section can include a flattened region so that air exiting the air-receiving section has a generally flattened profile.
-
-
-
-
-
-
-
-
-
搜索结果
858 条记录 (耗时 0.046 秒)
